Zinc supplementation in alcoholic cirrhosis
Zinc supplementation in alcoholic cirrhosis
批准号:
8644758
负责人:
Matthew C Cave
金额:
$19.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2016-03-31
关键词:
AccountingAdvisory CommitteesAlcohol consumptionAlcoholic Liver CirrhosisAlcoholic Liver DiseasesAlcoholic beverage heavy drinkerAlcoholismAmericanAnimal ModelAntioxidantsAttenuatedBiometryBlood CirculationBoard CertificationCell DeathCell WallCessation of lifeChildChronicCirrhosisClinicalClinical ResearchClinical Trials DesignDataDevelopmentDevelopment PlansDiseaseDoctor of MedicineDouble-Blind MethodDropsEndotoxemiaEndotoxinsEpithelialFDA approvedFibrosisFundingGenerationsGoalsGram-Negative BacteriaHealth BenefitHepatocyteHumanImmune systemInflammatoryInterdisciplinary StudyIntestinesKupffer CellsLiverMaster of ScienceMediator of activation proteinModelingMonitorMorbidity - disease rateMusOralOxidative StressPathway interactionsPatientsPermeabilityPharmaceutical PreparationsPlacebo ControlPlayPrimary carcinoma of the liver cellsPrincipal InvestigatorProductionPublishingRandomizedReactive Oxygen SpeciesReportingResearchResearch PersonnelResearch ProposalsRoleSafetySerumStagingStructureSupplementationTNF geneTechniquesTestingTight JunctionsToxicologyTranslational ResearchUnited StatesUniversitiesVenousWorkZincZinc SulfateZinc deficiencyalcohol researchanimal databasecareer developmentclinical practicecytokinehuman subjectimprovedliver injurymortalitynutritionpreventproblem drinkerprogramspublic health relevancetranslational approach
中文摘要
描述(由申请人提供):此K23应用程序将使马修洞穴,医学博士,他的目标是成为一名独立的研究者,专注于酒精性肝病(ALD)和营养的临床和转化研究。Cave博士将进行一项机制研究,评估硫酸锌治疗酒精性肝硬化(AC)患者的效果。Cave博士职业发展计划的亮点包括:(i)获得跨学科研究(I-MS)理学硕士学位,专注于毒理学,临床试验设计和生物统计学,以及(ii)营养学委员会认证(ABPNS)。这些活动将在最近资助的路易斯维尔大学酒精研究中心(P01)的环境中进行,并将由一个咨询委员会每季度进行监测。估计有200万美国人患有ALD,并且没有FDA批准的药物用于ALD的任何阶段。我们的初步数据记录了(i)患有AC的人类受试者中的锌缺乏,以及(ii)在小鼠模型中补充锌改善了肝损伤和肝损伤的假定机制。我们的假设是,硫酸锌治疗将导致改善的机制,假定在人类AC的发展和进展中发挥作用。为了检验这一假设,我们将在30名Child-Pugh A-B AC受试者中进行一项随机、双盲、安慰剂对照、“滴入”、硫酸锌220 mg每日一次的机制研究,为期24个月。主要终点是(i)血清内毒素血症和(ii)离体基础和内毒素刺激的TNF 1产生的减少。次要终点是(i)改善的血清锌状态,(ii)增加的肠紧密连接伴降低的渗透性,(iii)改善的血清促炎细胞因子谱,(iv)减少的氧化应激和改善的血清抗氧化状态,(v)减少的肝细胞死亡,(vi)减少的纤维化,和(vii)改善的临床状态。这些研究采用转化方法中的最新技术,以加深对AC潜在新疗法的理解。
英文摘要
DESCRIPTION (provided by applicant): This K23 application will enable Matthew Cave, M.D., to achieve his goal of becoming an independent investigator focusing on clinical and translational research in alcoholic liver disease (ALD) and nutrition. Dr. Cave will conduct a mechanistic study evaluating the effects of zinc sulfate therapy in patients with alcoholic cirrhosis (AC). Highlights of Dr. Cave's career development plan include: (i) obtaining a Master of Science degree in Interdisciplinary Studies (I-MS) focusing on toxicology, clinical trial design, and biostatistics, and (ii) board certification in nutrition (ABPNS). These activities will occur in the setting of the recently funded University of Louisville Alcohol Research Center (P01), and will be monitored quarterly by an advisory committee. An estimated two million Americans have ALD, and there are no FDA approved medications for any stage of ALD. Our preliminary data document (i) zinc deficiency in human subjects with AC, and (ii) improvement in liver injury and in postulated mechanisms of liver injury with zinc supplementation in murine models. Our hypothesis is that zinc sulfate therapy will result in improvement in mechanisms postulated to play a role in the development and progression of human AC. To test this hypothesis, we will perform a randomized, double blind, placebo-controlled, "drop in", mechanistic study of zinc sulfate 220 mg daily in 30 subjects with Child-Pugh A-B AC for 24 months. The primary endpoints are reduction in (i) serum endotoxemia and (ii) ex vivo basal and endotoxin-stimulated TNF1 production. Secondary endpoints are (i) improved serum zinc status, (ii) increased intestinal tight junctions with decreased permeability, (iii) improved serum pro-inflammatory cytokine profile, (iv) reduced oxidative stress and improved serum antioxidant status, (v) reduced hepatocyte death, (vi) decreased fibrosis, and (vii) improved clinical status. These studies utilize state- of-the art techniques in a translational approach to develop an enhanced understanding of a potential new therapy for AC.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1093/toxsci/kfv250
发表时间:
2016-02
期刊:
Toxicological sciences : an official journal of the Society of Toxicology
影响因子:
--
作者:
[B. Wahlang;R. Prough;K. Falkner;Josiah E. Hardesty;Ming Song;Heather B. Clair;B. Clark;J. States;G. Arteel;M. Cave]
通讯作者:
B. Wahlang;R. Prough;K. Falkner;Josiah E. Hardesty;Ming Song;Heather B. Clair;B. Clark;J. States;G. Arteel;M. Cave
Summer Environmental Health Sciences Training Program
-
批准号:10205784
-
项目类别:
-
资助金额:$4.97万
-
财政年份:2021
-
负责人:Matthew C Cave
-
依托单位:
Summer Environmental Health Sciences Training Program
-
批准号:10469317
-
项目类别:
-
资助金额:$5.12万
-
财政年份:2021
-
负责人:Matthew C Cave
-
依托单位:
m6A Epitranscriptomics in Toxicant Associated Steatohepatitis
-
批准号:10251386
-
项目类别:
-
资助金额:$2.34万
-
财政年份:2021
-
负责人:Matthew C Cave
-
依托单位:
Integrated Health Science Facility Core
-
批准号:10217137
-
项目类别:
-
资助金额:$11.65万
-
财政年份:2020
-
负责人:Matthew C Cave
-
依托单位:
Exposome and Precision Medicine in NAFLD
-
批准号:10248534
-
项目类别:
-
资助金额:$61.42万
-
财政年份:2020
-
负责人:Matthew C Cave
-
依托单位:
Integrated Health Science Facility Core
-
批准号:10600122
-
项目类别:
-
资助金额:$13.74万
-
财政年份:2020
-
负责人:Matthew C Cave
-
依托单位:
Exposome and Precision Medicine in NAFLD
-
批准号:10472017
-
项目类别:
-
资助金额:$60.3万
-
财政年份:2020
-
负责人:Matthew C Cave
-
依托单位:
m6A Epitranscriptomics in Toxicant Associated Steatohepatitis
-
批准号:10220036
-
项目类别:
-
资助金额:$28.86万
-
财政年份:2020
-
负责人:Matthew C Cave
-
依托单位:
Exposome and Precision Medicine in NAFLD
-
批准号:10064363
-
项目类别:
-
资助金额:$65.45万
-
财政年份:2020
-
负责人:Matthew C Cave
-
依托单位:
Integrated Health Science Facility Core
-
批准号:10386904
-
项目类别:
-
资助金额:$13.51万
-
财政年份:2020
-
负责人:Matthew C Cave
-
依托单位:
Environmental Liver Disease
-
批准号:9762903
-
项目类别:
-
资助金额:$51.72万
-
财政年份:2017
-
负责人:Matthew C Cave
-
依托单位:
Environmental Liver Disease
-
批准号:10004044
-
项目类别:
-
资助金额:$50.6万
-
财政年份:2017
-
负责人:Matthew C Cave
-
依托单位:
Environmental Liver Disease
-
批准号:9377237
-
项目类别:
-
资助金额:$55.09万
-
财政年份:2017
-
负责人:Matthew C Cave
-
依托单位:
Environmental Liver Disease
-
批准号:10248371
-
项目类别:
-
资助金额:$49.49万
-
财政年份:2017
-
负责人:Matthew C Cave
-
依托单位:
Biorepository and Animal Core
-
批准号:10026254
-
项目类别:
-
资助金额:$17.1万
-
财政年份:2016
-
负责人:Matthew C Cave
-
依托单位:
Biorepository and Animal Core
-
批准号:10608178
-
项目类别:
-
资助金额:$17.16万
-
财政年份:2016
-
负责人:Matthew C Cave
-
依托单位:
Biorepository and Animal Core
-
批准号:10377895
-
项目类别:
-
资助金额:$17.15万
-
财政年份:2016
-
负责人:Matthew C Cave
-
依托单位:
Tamburro Symposium on Environmental Chemicals and Liver Disease
-
批准号:8785871
-
项目类别:
-
资助金额:$1.54万
-
财政年份:2014
-
负责人:Matthew C Cave
-
依托单位:
PCBs worsen obesity/metabolic syndrome through 'toxic metabolic endotoxemia'
-
批准号:8467719
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2012
-
负责人:Matthew C Cave
-
依托单位:
PCBs worsen obesity/metabolic syndrome through 'toxic metabolic endotoxemia'
-
批准号:8618902
-
项目类别:
-
资助金额:$33.41万
-
财政年份:2012
-
负责人:Matthew C Cave
-
依托单位:
海外基金